ABSTRACT
A disintegrin and metalloproteinase 8 (ADAM8), a catalytically active member of the ADAMs family of enzymes, is expressed primarily on immune cells and thus probably involved in inflammatory responses. ADAM8 is also produced by chondrocytes, and recombinant ADAM8 can induce cartilage catabolism. We therefore decided to test the role of ADAM8 in autoimmune inflammatory arthritis using transgenic mice expressing catalytically inactive ADAM8. Transgenic DBA/1J mice expressing an inactivating point mutation in the ADAM8 gene to change Glu330 to Gln330 (ADAM8(EQ)) were generated to evaluate the proteolytic function of ADAM8 in an lipopolysaccharide-synchronized collagen-induced arthritis (LPS-CIA) model of autoimmune arthritis. The systemic inflammatory reaction to LPS was also evaluated in these mice. Expression profiling of paw joints from wild-type mice revealed that ADAM8 mRNA levels increased at the onset of clinical arthritis and correlated well with cellular macrophage markers. When subjected to LPS-CIA, ADAM8(EQ) mice demonstrated decreased incidence and severity of clinical arthritis compared to wild-type mice. Histological examination of paw joints from ADAM8(EQ) mice confirmed marked attenuation of synovial inflammation, cartilage degradation and bone resorption when compared to wild-type mice. However, transgenic mice and wild-type mice responded similarly to LPS-induced systemic inflammation with regard to mortality, organ weights, neutrophil sequestration and serum cytokine/chemokine production. We conclude that ADAM8 proteolytic activity plays a key role in the development of experimental arthritis and may thus be an attractive target for the treatment of arthritic disorders while minimizing risk of immunocompromise.
Subject(s)
ADAM Proteins/physiology , Antigens, CD/physiology , Arthritis, Experimental/metabolism , Arthritis, Rheumatoid/metabolism , Membrane Proteins/physiology , ADAM Proteins/genetics , ADAM Proteins/metabolism , Animals , Antigens, CD/genetics , Antigens, CD/metabolism , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/pathology , Autoantibodies/biosynthesis , Catalysis , Cells, Cultured , Collagen Type II/immunology , Cytokines/blood , Disease Progression , Gene Expression Profiling/methods , Glutamic Acid/genetics , Lipopolysaccharides/immunology , Male , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mice, Inbred DBA , Mice, Transgenic , Oligonucleotide Array Sequence Analysis/methods , Organ Size , Point Mutation , Severity of Illness IndexABSTRACT
OBJECTIVE: The objective of this study was to characterize the rat monosodium iodoacetate (MIA)-induced model for osteoarthritis (OA) and determine the translatability of this model to human disease. This was accomplished through pathway, network and system level comparisons of transcriptional profiles generated from animal and human disease cartilage. METHODS: An OA phenotype was induced in rat femorotibial joints following a single injection of 200mug MIA per knee joint for a period of 2 or 4 weeks. Lesion formation in the rat joints was confirmed by histology. Gene expression changes were measured using the Agilent rat whole genome microarrays. Cartilage was harvested from human knees and gene expression changes were measured using the Agilent human arrays. RESULTS: One thousand nine hundred and forty-three oligos were differentially expressed in the MIA model, of these, approximately two-thirds were up-regulated. In contrast, of the 2130 differentially expressed oligos in human disease tissue, approximately two-thirds were down-regulated. This dramatic difference was observed throughout each level of the comparison. The total overlap of genes modulated in the same direction between rat and human was less than 4%. Matrix degradation and inflammatory genes were differentially regulated to a much greater extent in MIA than human disease tissue. CONCLUSION: This study demonstrated, through multiple levels of analysis, that little transcriptional similarity exists between rat MIA and human OA derived cartilage. As disease modulatory activities for potential therapeutic agents often do not translate from animal models to human disease, this and like studies may provide a basis for understanding the discrepancies.
Subject(s)
Arthritis, Experimental/genetics , Cartilage, Articular/drug effects , Gene Expression Regulation/drug effects , Osteoarthritis/chemically induced , Transcription Factors/analysis , Transcription, Genetic/drug effects , Animals , Arthritis, Experimental/chemically induced , Arthritis, Experimental/pathology , Cartilage, Articular/pathology , Disease Models, Animal , Humans , Iodoacetates/administration & dosage , Iodoacetates/toxicity , Male , Osteoarthritis/genetics , Osteoarthritis/pathology , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction/methods , Statistics as TopicABSTRACT
OBJECTIVE: The signaling pathways induced by promegapoietin (PMP), a family of chimeric growth factors that activate the human IL-3 and c-Mpl receptors, were investigated. METHODS: The biological activity of PMP was examined by receptor binding, cell proliferation, ex vivo expansion of hematopoietic progenitor cells, and in vivo production of platelets. The activation of signaling pathways was examined by Western blot and Northern blot analyses. RESULTS: Two PMP molecules, PMP-1 and PMP-1a, induced proliferation of cells expressing the IL-3 receptor, c-Mpl, or both receptors and bound to the IL-3 receptor and c-Mpl with high affinity. Ex vivo expansion assays using human bone marrow CD34(+) cells suggested that PMP-1 induced greater total cellular expansion as well as expansion of CD41(+) megakaryocytic precursor cells than IL-3 or c-Mpl ligand alone. Subcutaneous administration of 50 microg/kg of PMP-1 for 10 days to rhesus monkeys resulted in increased platelet production in vivo from a baseline of 357 +/- 45 x 10(3) cells/mL to 1376 +/- 151 x 10(3) cell/mL. PMP-1 induced phosphorylation of the beta(c) subunit of IL-3 receptor and c-Mpl, JAK2, and STAT5b, but not STAT3. PMP-1 induced greater expression of Pim-1, c-Myc, and cyclin D2 than did either an IL-3 receptor agonist or c-Mpl receptor agonist alone. The magnitude of induction of early response genes was similar for PMP and the coaddition of IL-3 receptor agonist and c-Mpl receptor agonist. CONCLUSION: PMP combines the biological activities of IL-3 and c-Mpl ligand in a single molecule that can simultaneously activate signaling pathways induced by both these ligands.
Subject(s)
Growth Substances/pharmacology , Hematopoietic Stem Cells/cytology , Megakaryocytes/immunology , Milk Proteins , Neoplasm Proteins , Signal Transduction/immunology , Thrombopoietin/physiology , Amino Acid Sequence , Animals , Blood Platelets/cytology , Blood Platelets/drug effects , Blood Platelets/physiology , Bone Marrow Cells/cytology , Cell Division/drug effects , Cell Line , Cells, Cultured , Cloning, Molecular , DNA-Binding Proteins/metabolism , Female , Hematopoietic Stem Cells/drug effects , Humans , Interleukin-3 , Janus Kinase 2 , Macaca mulatta , Megakaryocytes/drug effects , Molecular Sequence Data , Phosphorylation , Phosphotyrosine/analysis , Phosphotyrosine/metabolism , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/physiology , Receptors, Cytokine/metabolism , Receptors, Interleukin-3/physiology , Receptors, Thrombopoietin , Recombinant Fusion Proteins/pharmacology , STAT5 Transcription Factor , Signal Transduction/drug effects , Trans-Activators/metabolism , TransfectionABSTRACT
The sequence of granulocyte colony-stimulating factor (G-CSF) has been circularly permuted by introducing new chain termini into interhelical loops and by constraining the N- and C-terminal helices, either by direct linkage of the termini (L0) or by substitution of the amino-terminal 10-residue segment with a seven-residue linker composed of glycines and serines (L1). All the circularly permuted G-CSFs (cpG-CSFs) were able to fold into biologically active structures that could recognize the G-CSF receptor. CD and NMR spectroscopy demonstrated that all of the cpG-CSFs adopted a fold similar to that of the native molecule, except for one [cpG-CSF(L1)[142/141]] which has the new termini at the end of loop 34 with the shorter L1 linker. All of the cpG-CSFs underwent cooperative unfolding by urea, and a systematically lower free energy change (DeltaGurea) was observed for molecules with the shorter L1 linker than for those molecules in which the original termini were directly linked (the L0 linker). The thermodynamic stability of the cpG-CSFs toward urea was found to correlate with their relative ability to stimulate proliferation of G-CSF responsive cells. Taken together, these results indicate that the G-CSF sequence is robust in its ability to undergo linear rearrangement and adopt a biologically active conformation. The choice of linker, with its effect on stability, seems to be important for realizing the full biological activity of the three-dimensional structure. The breakpoint and linker together are the ultimate determinants of the structural and biological profiles of these circularly permuted cytokines. In the following paper [McWherter, C. A., et al. (1999) Biochemistry 38, 4564-4571], McWherter and co-workers have used circularly permuted G-CSF sequences to engineer chimeric dual IL-3 and G-CSF receptor agonists in which the relative spatial orientation of the receptor agonist domains is varied. Interpreting the differences in activity for the chimeric molecules in terms of the connectivity between domains depends critically on the results reported here for the isolated cpG-CSF domains.
Subject(s)
Granulocyte Colony-Stimulating Factor/chemistry , Granulocyte Colony-Stimulating Factor/genetics , Protein Engineering , Recombinant Fusion Proteins/chemical synthesis , Recombinant Fusion Proteins/metabolism , Amino Acid Sequence , Animals , Binding Sites/genetics , Cell Division/drug effects , Cell Line , Circular Dichroism , Granulocyte Colony-Stimulating Factor/metabolism , Granulocyte Colony-Stimulating Factor/pharmacology , Humans , Kinetics , Membrane Proteins/metabolism , Mice , Nuclear Magnetic Resonance, Biomolecular , Protein Conformation , Protein Denaturation , Protein Engineering/methods , Protein Folding , Protein Structure, Secondary , Receptors, Granulocyte Colony-Stimulating Factor/chemistry , Receptors, Granulocyte Colony-Stimulating Factor/metabolism , Recombinant Fusion Proteins/pharmacology , Structure-Activity Relationship , Surface Plasmon Resonance , Thermodynamics , Urea/chemistryABSTRACT
To establish a direct link between IL-8 and inflammation in vivo, we first isolated the gene encoding rhesus macaque IL-8. The open reading frame directs the translation of a 101 amino acid (aa) precursor, which is 94% identical to human IL-8. Rhesus IL-8 was expressed in bacteria and purified to homogeneity with ion-exchange chromatography. Pure rhesus IL-8 was biologically active as measured by its ability to bind specifically to either rhesus (Kd = 0.5 nM) or human (Kd = 2 nM) IL-8 receptors and to promote in vitro chemotaxis of rhesus (EC50 = 2 nM) or human neutrophils (EC50 = 4 nM). Moreover, a mouse monoclonal antibody, DM/C7, which neutralizes human IL-8 activity, also recognized and neutralized (IC50 = 0.5-3.0 microgram/ml) rhesus IL-8 in vitro. Systemic administration of DM/C7 completely inhibited the dermal inflammation of rhesus ears induced by the external application of phorbol myristoyl acetate. These observations reveal that rhesus IL-8 is structurally and functionally similar to human IL-8 and suggests that IL-8 plays a prominent role in a primate model of inflammation.
Subject(s)
Interleukin-8/isolation & purification , Macaca mulatta/metabolism , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Base Sequence , Chemotaxis, Leukocyte/drug effects , Chromatography, Ion Exchange , Cloning, Molecular , Edema/chemically induced , Edema/physiopathology , Edema/prevention & control , Female , Genes , Humans , Inflammation , Interleukin-8/antagonists & inhibitors , Interleukin-8/genetics , Interleukin-8/immunology , Interleukin-8/pharmacology , Macaca mulatta/genetics , Mammals/genetics , Molecular Sequence Data , Neutrophils/drug effects , Open Reading Frames , Sequence Homology, Amino Acid , Species Specificity , Tetradecanoylphorbol Acetate/toxicityABSTRACT
Myristoyl-CoA:protein N-myristoyltransferase (NMT) has recently been identified as a target for antiviral and antifungal therapy. Candida albicans is a dimorphic, asexual yeast that is a major cause of systemic fungal infections in immunosuppressed humans. Metabolic labeling studies indicate that C. albicans synthesizes one principal 20-kDa N-myristoyl-protein. The single copy C. albicans NMT gene (ca-NMT1) was isolated and encodes a 451-amino acid protein that has 55% identity with Saccharomyces cerevisiae NMT. C. albicans NMT1 is able to complement the lethal phenotype of S. cerevisiae nmt1 null mutants by directing efficient acylation of the approximately 12 endogenous N-myristoylproteins produced by S. cerevisiae. C. albicans NMT was produced in Escherichia coli, a prokaryote with no endogenous NMT activity. In vitro studies of purified E. coli-derived S. cerevisiae and C. albicans NMTs revealed species-specific differences in the kinetic properties of synthetic octapeptide substrates derived from known N-myristoylproteins. Together these data indicate that C. albicans and S. cerevisiae NMTs have similar yet distinct substrate specificities which may be of therapeutic significance.